Bempedoic Acid in Statin-Intolerant Patients: Real-World Implementation Strategies, Cardiovascular Outcomes Beyond the CLEAR Trial, and Combination Therapy Approaches
Statin intolerance remains a significant barrier to achieving lipid goals and reducing atherosclerotic cardiovascular disease (ASCVD) risk. Bempedoic acid (BA), an oral ATP-citrate lyase inhibitor activated predominantly in the liver, offers a non-statin lipid-lowering option with a low propensity for muscle-related ad...